SynthesisPituitary2015
Silent corticotroph adenomas.
Synthesis in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.Endocrine · 2023Pooled it
- Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.Pituitary · 2018Pooled it
- GATA3-positive silent corticotroph adenomas are characterized by large size and massive infrasellar invasion.Pituitary · 2026Article
- Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.Pituitary · 2026Article
- Predicting recurrence in silent corticotroph adenomas: a habitat analysis and comprehensive nomogram approach.Neuroradiology · 2026Article
- Management of a mixed ACTH- and prolactin-secreting pituitary adenoma during pregnancy.Endocrinology, diabetes & metabolism case reports · 2025Article
- Radiomics based on preoperative magnetic resonance imaging predict the cell lineages of nonfunctioning pituitary neuroendocrine tumors.Neuroradiology · 2025Article
- Radiological and Immunohistochemical Characteristics of PitNETs in 79 Patients Undergoing Neurosurgery.Cancers · 2025Article
- The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.Scientific reports · 2023Article
- Aggressive nonfunctioning pituitary neuroendocrine tumors.Brain tumor pathology · 2022Review
- Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature.Journal of neurological surgery reports · 2022Article
- Silent Corticotroph Tumor with Adrenocortical Choristoma in an Eleven-year-old BoyJournal of clinical research in pediatric endocrinology · 2022Article
- Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.European radiology · 2022Article
- Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.Frontiers in endocrinology · 2022Article
- An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.Cancers · 2021Review
- Article
- The silent variants of pituitary tumors: demographic, radiological and molecular characteristics.Journal of endocrinological investigation · 2021Observational
- Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.Frontiers in endocrinology · 2021Review
- Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purposeSilent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs.
methodsA systematic literature review was performed using PubMed for information regarding SCAs.
resultsUp to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented.
conclusionThis review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.